Antigeenpresentatie bij SARS-CoV-2-infectie: de rol van klasse I HLA- en ERAP-polymorfismen
Gezien de zeer polymorfe aard van humaan leukocytenantigeen (HLA)-moleculen, is het niet verwonderlijk dat ze fungeren als belangrijke regulatoren van de immuunrespons van de gastheer op bijna alle binnendringende pathogenen, waaronder SARS-CoV-2 , het etiologische agens dat verantwoordelijk is voor de recente COVID-19 -19 pandemie. Er zijn al verschillende correlaties vastgesteld tussen de expressie van een specifiek HLA-allel/haplotype en gevoeligheid/progressie van SARS-CoV-2-infectie en er komen voortdurend nieuwe bij. Beschermende en schadelijke HLA-varianten zijn beschreven in zowel milde als ernstige vormen van de ziekte, maar gezien de enorme hoeveelheid bestaande varianten zijn de gegevens die in zo’n korte tijdspanne zijn verzameld tot op zekere hoogte verwarrend en tegenstrijdig.
Het doel van deze mini-review is om een momentopname te geven van de belangrijkste bevindingen die tot nu toe zijn verzameld over de HLA-SARS-CoV-2-interactie, om dit ingewikkelde garen gedeeltelijk te ontwarren. Als sleutelfactoren bij het genereren van antigene peptiden die door HLA-moleculen moeten worden gepresenteerd , zal ook de rol van ERAP1 en ERAP2 bij SARS-CoV-2-infectie worden herzien.
Beoordeling van immunogeniciteit en veiligheid in twee productiepartijen van een 3- antigeen hepatitis B-vaccin, Sci-B-Vac®, vergeleken met Engerix-B® bij gezonde Aziatische volwassenen: een gerandomiseerde klinische fase 3-studie
Achtergrond: Sci-B-Vac®, een 3-antigeen hepatitis B-vaccin (3A-HBV), bevat alle drie de envelopeiwitten van het recombinante hepatitis B-virus (HBV) (S, pre-S1 en pre-S2). In 2005 verplaatste de productie van 3A-HBV de faciliteiten (A naar B), waar het nog steeds wordt geproduceerd.
Methoden: Deze fase 3, enkelblinde, gerandomiseerde studie, uitgevoerd op één locatie in Vietnam, vergeleek de werkzaamheid en veiligheid tussen twee 3A-HBV-partijen, partij A en partij B, en een enkel antigeen hepatitis B-vaccin (1A-HBV) , Engerix-B®. Het primaire doel was om op dag 210 gelijkwaardigheid aan te tonen van twee 3A-HBV-lots in seroprotectiepercentage (SPR; gedefinieerd als proportion deelnemers dat hepatitis B-oppervlakteantigeenantilichaam [anti-HBs]-titers ≥ 10 mIU/ml bereikte). Secundaire doelstellingen waren het beoordelen van de immunogeniciteit op dag 180, 210 en 360, en de veiligheid van 3A-HBV.
Resultaten: 3A-HBV SPR-equivalentie werd aangetoond op dag 210 (partij A: 97,3% [95% BI: 92,4%, 99,4%] vs. partij B: 100,0% [97,0%, 100,0%]). Vergeleken met 1A-HBV was de SPR van partij B hoger op dag 180 (98,3% vs. 81,2%; verschil: 17,1% [9,7%, 24,6%]) en niet-inferieur op dag 210 (100% vs. 98,3%; verschil : 1,7% [-0,6%, 4,1%]). 3A-HBV partij B vertoonde dezelfde SPR na 2 doses (98,3%) als 1A-HBV na Three doses (98,3%). Bijwerkingen (AE’s) waren vergelijkbaar met beide 3A-HBV-partijen (partij A: 68,7% vs. partij B: 54,2%), maar hoger dan 1A-HBV (35,3%). Vaccinatiegerelateerde bijwerkingen omvatten voorbijgaande pijn op de injectieplaats (38,9%), myalgie (9,3%) en vermoeidheid (7,5%). Er werden acht ernstige bijwerkingen gemeld (partij A: 3/134 [2,2%]; partij B: 1/134 [0,8%]; 1A-HBV: 4/133 [2,3%]). Eén ernstige AE, syncope, werd opgemerkt als waarschijnlijk gerelateerd aan onderzoeksvaccin, lot B.
Conclusies: De twee 3A-HBV-partijen hadden een gelijkwaardige immunogeniciteit, maar partij B veroorzaakte een snellere aanvang van seroprotectie en hogere anti-HBs-titers dan zowel partij A als 1A-HBV in een Aziatische populatie. Dit ondersteunt 3A-HBV lot B als een effectieve keuze voor HBV-vaccinatie, met een gunstig veiligheidsprofiel.
Description: This kit is a highly sensitive and specific enzyme immunoassay for the detection of Influenza A nucleoprotein antigen in complex sample matrices derived from both human and veterinary sources.
Influenza A Strain A/Solomon Islands/03/06 (H1N1) Antigen Liquid
Description: Avian Influenza A M2 Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. Novel influenza virus strains caused by genetic drift and viral recombination emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however, it is in birds that all subtypes can be found. These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. During 1997, an H5N1 avian influenza virus was determined to be the cause of death in 6 of 18 infected patients in Hong Kong. The more recent virulent strain of H5N1 is now seen in Africa and Europe, as well as in Southeast Asia. There is some evidence of human to human spread of this virus, but it is thought that the transmission efficiency was fairly low. The influenza membrane ion channel (M2) is a small transmembrane protein that regulates the pH inside the virion during viral entry into the cell and protects the newly synthesized hemagglutinin during their transport through low pH cellular compartments. It has been suggested as a target of neutralizing antibodies.
Description: Avian Influenza A M2 Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. Novel influenza virus strains caused by genetic drift and viral recombination emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however, it is in birds that all subtypes can be found. These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. During 1997, an H5N1 avian influenza virus was determined to be the cause of death in 6 of 18 infected patients in Hong Kong. The more recent virulent strain of H5N1 is now seen in Africa and Europe, as well as in Southeast Asia. There is some evidence of human to human spread of this virus, but it is thought that the transmission efficiency was fairly low. The influenza membrane ion channel (M2) is a small transmembrane protein that regulates the pH inside the virion during viral entry into the cell and protects the newly synthesized hemagglutinin during their transport through low pH cellular compartments. It has been suggested as a target of neutralizing antibodies.
Description: Goat polyclonal Influenza A antibody (H1N1) (FITC) conjugated
×
Op glasplaatjes gedrukte eiwitarrays als platform om serodiagnostische antigenen tegen bacteriële infecties te ontdekken
Infectieziekten vormen wereldwijd een belangrijke oorzaak van morbiditeit en mortaliteit. Vroege opsporing van infecties is van cruciaal belang voor het beheer van levensbedreigende gevallen . Tot nu toe zijn traditionele diagnostische methoden, zoals microbiologische culturen, traag en soms onnauwkeurig. In het moleculaire tijdperk zijn high-throughput-technieken essentieel voor het leveren van hulpmiddelen die in staat zijn om op een snelle en betrouwbare manier een diagnose te stellen, en ze kunnen ook worden gebruikt voor het bewaken van de humorale respons van groepen mensen in een programma van epidemiologische surveillance wanneer een uitbraak plaatsvindt, of wanneer een vaccin wordt geëvalueerd. Op antigeen gebaseerde eiwitmicroarrays zijn een ideaal middelvoor deze doeleinden, aangezien ze tot duizenden eiwitantigenen van pathogene bronnen kunnen dragen en kunnen worden onderzocht met sera van verschillende menselijke groepen (acute of chronisch geïnfecteerde mensen, herstellende, controles).
Voor de diagnose van bacteriële infecties zijn de beste antigenen in principe de oppervlakte-eiwitten, omdat deze de grootste kans hebben om een effectieve immuunrespons op te wekken. Hier beschrijven we een algemeen protocol voor het fabriceren van een op glasplaatjes gebaseerde eiwitmicroarray met behulp van recombinante bacteriële oppervlakteantigenen, volgens onze eigen experience in de studie van pneumokokkenziekte. Het sonderen met menselijke sera heeft tot doel de verschillen tussen zieke en gezonde mensen te evalueren , om onderscheidende antigenen te ontdekken die, na gepaste validatie, kunnen worden gebruikt in andere gebruiksvriendelijke formaten zoals immunostrips.
Antigeen- presenterende, zelf-geassembleerde eiwit-nanovaten als een adjuvans-vrij vaccinplatform tegen het influenzavirus
Hoewel ze van nature voorkomen, zijn zelf-geassembleerde eiwit-nanoarchitecturen gebruikt als dragers voor het afleveren van antigeen, en het onvermogen van dergelijke dragers om immunogeniciteit op te wekken vereist aanvullend gebruik van sterke adjuvantia. Hier rapporteren we een immunogene Brucella- buitenmembraaneiwit BP26-afgeleide nanoarchitectuur die het extracellulaire influenzadomein van matrixproteïne-2 (M2e) als een vaccinplatform tegen influenzavirus weergeeft. Genetische manipulatie van een monomeer BP26 met vier of acht tandemherhalingen van M2e resulteerde in een holle tonvormige nanoarchitectuur (BP26-M2e nanobarrel). Immunisatie met BP26-M2e nanobarrels induceerde in vivo een sterke M2e-specifieke humorale immuunrespons dat was veel groter dan dat van een fysisch mengsel van oplosbaar M2e en BP26, met of zonder het gebruik van een aluin-adjuvans.
Een anti- M2e- antilichaam gegenereerd door met BP26-M2e nanobarrel geïmmuniseerde muizen, specifiek gebonden aan met het influenzavirus geïnfecteerde cellen. Bovendien beschermden BP26-M2e-nanobarrels in virale challenge-tests muizen effectief tegen sterfte door influenzavirusinfectie, zelfs zonder het gebruik van een conventioneel adjuvans. Een mechanismestudie onthulde dat zowel M2e-specifieke antilichaamafhankelijke cellulaire cytotoxiciteit als T-celresponsen betrokken zijn bij de vaccineffectiviteit van BP26-M2e nanovaten. Deze bevindingen suggereren dat het op BP26 gebaseerde nanovat dat hier is ontwikkeld een veelzijdig vaccinplatform vertegenwoordigt dat kan worden gebruikt tegen verschillende virale infecties.
Prognostische impression van 18F-FDG PET/CT bij patiënten met agressief B-cellymfoom behandeld met anti-CD19 chimere antigeenreceptor T-cellen
Doel van het rapport: We wilden de rol van 18F-FDG PET/CT evalueren bij het voorspellen van de uitkomst van de patiënt na infusie van chimere antigeenreceptor T (CAR T)-cellen bij agressief B-cellymfoom.
Methoden: 18F-FDG PET/CT-gegevens vóór leukaferese, vóór CAR T-celinfusie en 1 maand (M1) na CAR T-celinfusie, van 72 patiënten werden retrospectief geanalyseerd. SUVmax, totale laesie-glycolyse (TLG), metabool tumorvolume (MTV) en parameters die de tumorkinetiek beschrijven, werden berekend voor elke uitgevoerde 18F-FDG PET/CT. Het doel was om de prognostische waarde van 18F-FDG PET/CT metabole parameters te evalueren voor het voorspellen van progressievrije overleving (PFS) en algehele overleving (OS) na CAR T-celtherapie.
Resultaten: Met betrekking tot PFS bleken [INCREMENT]MTVpre-CAR en [INCREMENT]TLGpre-CAR meer discriminerend te zijn in vergelijking met metabole parameters bij pre-infusie. De mediane PFS bij patiënten met een [INCREMENT]MTVpre-CAR van minder dan 300% was 6,eight maanden (95% betrouwbaarheidsinterval [BI], 2,eight maanden tot niet bereikt) vergeleken met 2,eight maanden (95% BI, 0,9-3,Zero maanden) voor die met een waarde van 300% of meer (P = 0,004). Evenzo was de mediane PFS bij patiënten met [INCREMENT]TLGpre-CAR van minder dan 420% 6,eight maanden (95% BI, 2,eight maanden tot niet bereikt) vergeleken met 2,7 maanden (95% BI, 1,3-3,Zero maanden) voor degenen met een waarde van 420% of meer (P = 0,0148). Met betrekking tot OS waren metabole parameters op M1 sterk geassocieerd met de daaropvolgende uitkomst. SUVmax bij M1 met een afkapwaarde van 14 was de meest voorspellende parameter in multivariate analyse,
Conclusies: De metabole volumekinetiek van de ziekte vóór infusie van CAR T-cellen lijkt superieur te zijn aan de initiële tumormassa zelf voor het voorspellen van PFS. Voor OS kan SUVmax bij M1 patiënten met verschillende prognoses adequaat scheiden.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.
Description: NK-1.1 is commonly used as a mouse NK cell marker. It has also been shown to play a role in NK cell activation, IFN- production, and cytotoxic granule release. It is a type II integral membrane glycoprotein with a C-type lectin domain and is encoded by the Klrb1c/NKR-P1C gene. It is predominantly expressed as a disulfide-linked homodimer on NK cells however; it is also expressed on NK-T cells, a rare population of T lymphocytes. NK1.1 is expressed in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo.
Description: NK-1.1 is commonly used as a mouse NK cell marker. It has also been shown to play a role in NK cell activation, IFN- production, and cytotoxic granule release. It is a type II integral membrane glycoprotein with a C-type lectin domain and is encoded by the Klrb1c/NKR-P1C gene. It is predominantly expressed as a disulfide-linked homodimer on NK cells however; it is also expressed on NK-T cells, a rare population of T lymphocytes. NK1.1 is expressed in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo.
Description: NK-1.1 is commonly used as a mouse NK cell marker. It has also been shown to play a role in NK cell activation, IFN- production, and cytotoxic granule release. It is a type II integral membrane glycoprotein with a C-type lectin domain and is encoded by the Klrb1c/NKR-P1C gene. It is predominantly expressed as a disulfide-linked homodimer on NK cells however; it is also expressed on NK-T cells, a rare population of T lymphocytes. NK1.1 is expressed in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo.
Description: This mAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This mAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions. It produces a speckled pattern in normal and malignant cells and may be used to stain the nuclei of cells in fixed tissue sections.
Description: This mAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This mAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions. It produces a speckled pattern in normal and malignant cells and may be used to stain the nuclei of cells in fixed tissue sections.
Description: This mAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This mAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions. It produces a speckled pattern in normal and malignant cells and may be used to stain the nuclei of cells in fixed tissue sections.
Description: This mAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This mAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions. It produces a speckled pattern in normal and malignant cells and may be used to stain the nuclei of cells in fixed tissue sections.
Description: This MAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This MAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions.
Description: This MAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This MAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions.
Description: This MAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This MAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions.
Description: This mAb recognizes an antigen associated with the nuclei in cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions.
Description: This mAb recognizes an antigen associated with the nuclei in cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions.
Description: This mAb recognizes an antigen associated with the nuclei in cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions.
Description: This mAb recognizes an antigen associated with the nuclei in cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions.
Description: This MAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This MAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions. It produces a speckled pattern in normal and malignant cells.
Description: This MAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This MAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions. It produces a speckled pattern in normal and malignant cells.
Description: This MAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This MAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions. It produces a speckled pattern in normal and malignant cells.
Description: This MAb is an excellent marker for all nuclei in cells in tissues. It is a part of a new panel of reagents, which recognizes subcellular organelles or compartments of cells. These markers may be useful in identification of these organelles in cells, tissues, and biochemical preparations. This MAb recognizes an antigen associated with the nuclei in all cells. It can be used to stain the nuclei in cell or tissue preparations and can be used as a nuclear marker in subcellular fractions. It produces a speckled pattern in normal and malignant cells.
Lymphocyte Antigen 9 (LY9) Polyclonal Antibody (Human), PE
